30 closest matches · ranked by relevance
Recurrent Vulvovaginal Candidiasis
Primary: Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population — 5.1; 42.2…
Vulvovaginal Candidiasis
Primary: Candida Culture Free After Maintenance Therapy — 18; 19; 9 participants
Recurrent Vulvovaginal Candidiasis
Primary: Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population. — 3.9; 39.4…
Recurrent Vulvovaginal Candidiasis
Primary: Percentage of Subjects With 1 or More Culture-Verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-Treat Population — 6.7; 42.8…
Recurrent Vulvovaginal Candidiasis
Primary: Clinical Success — 85; 69; 45; 61 Participants
Vulvovaginal Candidiasis
Primary: Summary of Injection Site Reactions for the Safety Population Over the 12-months Post Vaccination Period — 72; 79; 10; 25 AEs
Recurrent Vulvovaginal Candidiasis
Primary: The Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes Through Week 48 of the Study in the Intent-to-treat Population. — 2; 3; 0; 2 Participants
Vulvovaginal Candidiasis
Primary: Clinical Cure — 7; 10; 23 Participants
Vulvovaginal Candidiasis
Primary: Therapeutic Outcome: Response Rate — 33.7; 54.2; 74.7 percentage of participants
Bacterial Vaginosis
Primary: Recurrent Bacterial Vaginosis — 7; 7 Participants — p=0.75
Candidiasis, Vulvovaginal
Primary: Therapeutic Efficacy 1 — 102; 98 participants — p=0.925
Vulvovaginal Candidiasis
Primary: Mycological Cure 1 — 46; 47 Participants
Candida Vulvovaginitis
Primary: Clinical Cure (Complete Resolution of Signs and Symptoms) — 9; 14; 13; 14 Participants
Vulvovaginitis · Yeast Infection · Yeast Infection Vaginal
Primary: Clinical Outcome Assessed at Test of Cure Visit — 13; 12; 24; 12 Participants
Vulvovaginal Candidiasis
Primary: Dose-response of Clinical and Mycological (Global) Therapeutic Response — 31.7; 48.7; 47.6; 53.8 percentage of patients cured — p=0.0630
Candida Vulvovaginitis
Primary: Clinical Cure (Complete Resolution of Signs and Symptoms) — 119; 37; 69; 47 Participants
Candidiasis, Vulvovaginal
Primary: Percentage of Subjects With Therapeutic Cure at 28 Days for All-Analysis Population — 9; 9; 11; 10 Participants
Vulva; Candidiasis
Primary: Mean Time to Itch Relief — 13.36 minutes
Bacterial Vaginosis
Primary: The Proportion of Participants Reporting Product-related Adverse Events (AEs) and Serious Adverse Events (SAEs) in Each Study Arm. — 0.11; 0.07 proportion of…
Urinary Tract Infection
Primary: Incidence of Urinary Tract Infection — 7; 13 participants
Bacterial Vaginosis
Primary: Bacterial Vaginosis (BV) Incidence by Modified Amsel Criteria — 7.53; 2.04; 3.36; 3.35 Incidence: events per PY at risk
Recurrent Bacterial Vaginosis
Primary: Number of Subjects With at Least One Episode of Bacterial Vaginosis — 8 Participants
Recurrent Respiratory Papillomatosis
Primary: Change in Papilloma Severity — 13.2; 12; 3.7; 3.6 scores on a scale
Bacterial Vaginosis · Candidiasis · Trichomoniasis
Primary: Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights…
Vulvovaginal Candidiasis
Primary: Clinical Cure Rate at Day 7-14 — 10; 16 Participants
Candida Vulvovaginitis
Primary: Clinical Cure (Complete Resolution of Signs and Symptoms) — 95; 28; 93; 70 Participants
Bacterial Vaginosis
Primary: Quantity of BV-associated Bacteria by qPCR and High-throughput Sequencing Tests — 5.59; 5.22; 4.91; 7.41 log10 copies/ml — p=0.011
Trichomonas Infections · HIV Infections
Primary: TV Culture Positive Result — 11; 21 participants — p=.045
Vulvovaginal Candidiasis
Primary: Clinical Cure Rate — 9 Participants
Vaginitis Trichomonal or Due to Trichomonas
Primary: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) — 58; 34 Participants